MedTrace Logo

Study Evaluating LDL-C Change and Adherence to Inclisiran Lipid-lowering Therapy in ASCVD

NCT05399992 · Status: ACTIVE_NOT_RECRUITING · Type: OBSERVATIONAL · Enrollment: 847

Last updated 2026-02-03

No results posted yet for this study

Summary

This observational prospective study aims to evaluate the LDL-C change and adherence to inclisiran in combination with other lipid lowering therapies or lipid lowering treatments (LLTs) under conditions of routine clinical practice.

Conditions

  • Primary Hypercholesterolemia
  • Mixed Dyslipidemia

Interventions

OTHER

Inclisiran

Prospective observational study. There is no treatment allocation. Patients who are eligible to receive inclisiran will be enrolled into this study.

Sponsors & Collaborators

Principal Investigators

  • Novartis Pharmaceuticals · Novartis Pharmaceuticals

Eligibility

Min Age
18 Years
Max Age
100 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-09-12
Primary Completion
2026-10-05
Completion
2026-10-05

Countries

  • Austria
  • China
  • Israel
  • Malaysia
  • Saudi Arabia
  • Switzerland
  • United Arab Emirates
  • United Kingdom

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05399992 on ClinicalTrials.gov